MannKind Corporation
Financials
Valuation Metrics
MannKind Corporation's Market Cap is $1.17B. At end of 2025 it was $1.73B. Ranked #2358 of 3,116 in US market (top 76%), #951 of 1,472 on NASDAQ (top 65%), #173 of 265 in Pharmaceuticals, Biotechnology & Life Sciences (top 65%) by Market Cap.
Investment Metrics(as of 2026-11-02)
| Metric | Value | Rank |
|---|---|---|
| Size | ||
| Market Cap | $1.17B | US#2,358/3,116 Sec#173/265 |
| Revenue | $394M | US#2,334/3,116 Sec#86/265 |
| Net Income | $-44M | US—/3,116 Sec—/265 |
| Total Assets | $732M | US#2,600/3,116 Sec#127/265 |
| Net Assets | $-67M | US#2,947/3,116 Sec#248/265 |
| Employees | 592 | US#2,200/3,116 Sec#77/265 |
| Value | ||
| P/S | 2.98x | US#1,632/3,116 Sec#48/265 |
| EV/EBITDA | 47.21x | US#2,340/3,116 Sec#71/265 |
| FCF Yield | -1.58% | US—/3,116 Sec—/265 |
| Profitability | ||
| ROA | -5.96% | US#2,561/3,116 Sec#91/265 |
| Op. Margin | 1.97% | US#2,218/3,116 Sec#77/265 |
| Revenue Growth | 30.46% | US#412/3,116 Sec#62/265 |
| Earnings Growth | -232.98% | US#1,938/3,116 Sec#63/265 |
| Financial Health | ||
| Total Debt | $331M | US#2,057/3,116 Sec#75/265 |
| FCF | $-19M | US#2,411/3,116 Sec#94/265 |
| Cash | $53M | US#2,550/3,116 Sec#222/265 |
| Current Ratio | 1.72x | US#1,444/3,116 Sec#230/265 |
| Net Debt/EBITDA | 9.04x | US#2,333/3,116 Sec#81/265 |
| Performance | ||
| 1Y Return | -34.70% | US#2,707/3,116 Sec#222/265 |
| 1M Return | -3.95% | US#1,307/3,116 Sec#88/265 |
| From 52W High | -43.93% | US#2,570/3,116 Sec#193/265 |
| 1Y MDD | -63.28% | US#2,807/3,116 Sec#216/265 |
| Trading | ||
| Volume | 3,149,553 shares | US#826/3,116 Sec#74/265 |
| Trading Value | $11M | US#2,428/3,116 Sec#198/265 |
| Per Share | ||
| EPS | $-0.14 | US—/3,116 Sec—/265 |
| BPS | $-0.21 | US—/3,116 Sec—/265 |
Company Info
MannKind Corporation operates as a biopharmaceutical firm, primarily focused on innovating and bringing to market respiratory-delivered treatments. Its efforts are directed towards tackling endocrine system disorders and rare lung conditions within the U.S. market. The company's key product is Afrezza, an inhaled insulin designed to improve glycemic control for adults managing diabetes. MannKind also actively markets Thyquidity, promoting it to adult and pediatric endocrinologists and other healthcare professionals for the treatment of hypothyroidism. In terms of collaborations, MannKind holds a strategic licensing and partnership agreement with United Therapeutics Corporation. Furthermore, it is collaborating with NRx Pharmaceuticals to develop a dry powder formulation of ZYESAMI (aviptadil), which is a synthetic variant of human vasoactive intestinal peptide intended to shield cells from inflammatory processes. Established in 1991, MannKind Corporation's corporate offices are located in Westlake Village, California.